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Abstract
Background: Gastrin has been shown to exert carcinogenic effect 
to the epithelium of the colon. This study examines whether hy-
pergastrinemia and H. pylori infection -especially infection by the 
CagA+ strain- are statistically associated with colorectal cancer and 
examine possible correlations with the colorectal cancer stage and 
lymph node metastasis.
Methods:  In  this  prospective  case-control  study,  fasting  serum 
samples from 93 consecutive patients with colorectal cancer treated 
in a university surgical clinic were preoperatively collected and se-
rum levels of gastrin were measured. A group of 20 age matched 
hernia patients were used as controls. The pathology report of the 
specimens  was  documented  and  statistical  analysis  of  the  data 
where performed with the spss 17 statistical suite.
Results: H. pylori IgG antibodies was reported in 66/93 (71%) in 
the colorectal cancer group and 13/20 patients in the control group 
(65%), the difference having non-statistical significance (P = n.s). 
The prevalence of cagA protein expression in the anti- H. pylori 
IgG+ patients were  higher in the colorectal cancer group (56% 
positivity), when compared to the control group (38,4% positiv-
ity) but the difference was not of statistical significance (P = n.s). 
The mean levels of serum gastrin levels in the two groups did not 
significantly differ (Ca group 51.1 ± 36.6 pg/mL vs Control 49.8 
± 17.6 P = n.s.). Patients with lymph node metastasis had higher 
serum gastrin levels than patients without metastasis and this differ-
ence was statistically significant. (53.6 vs 41.06 pg/mL P = 0.025).
Conclusions: Although the serum gastrin levels were not statisti-
cally different between the TNM stages of our patient cohort, our 
data found that serum gastrin levels were significantly higher in pa-
tients with lymph node metastasis. Whether gastrin is implicated in 
the ability of cancer cells to metastasize to the lymph nodes merits 
further research.
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Introduction
Helicobacter  pylori  infection  and  hypergastrinemia  are 
considered to be related to the development of colorectal 
cancer. However, the results of previously conducted stud-
ies showed controversial findings, not being able to either 
reject or clearly support a direct correlation between H. py-
lori infection and/or elevated gastrin levels with colorectal 
carcinogenesis.
H. pylori is recognized as a class I human carcinogen, 
according to the International Agency for Research on Can-
cer  [1]. Although,  H.  pylori  infection  has  been  causative 
associated with gastric carcinoma and lymphoma, its role 
in  colorectal  cancer  development  remains  unclarified  [2]. 
A  possible  pathogenetic  mechanism  involves  the  persis-
tent H. pylori colonization and inflammation of the gastric 
mucosa, particularly when the H. pylori strains express the 
cytoxin-associated gene (CagA) which often results in the 
development of chronic atrophic gastritis and subsequently 
hypergastrinemia, through a reverse-feedback mechanism; 
hypergastrinemia is considered to be a possible risk factor 
for the development of colorectal cancer [3-5].
The aim of our case-control study is to examine whether 
hypergastrinemia and H. pylori infection -especially infec-
tion by the CagA+ strain- are statistically associated with 
colorectal cancer and examine possible correlations with the 
colorectal cancer stage and lymph node metastasis.
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Methods
The study population of this prospective case-control study 
included  colorectal  cancer  patients  admitted  for  surgical 
treatment in a university hospital’s surgical department and 
a  demographically  matched  patient  population  who  were 
scheduled for hernia repair as a control group.
Fasting serum samples were obtained from all patients, 
in order to assay anti-H. pylori immunoglobulin G, CagA 
protein  expression  and  serum  gastrin  levels. An  enzyme-
linked immunosorbent assay (ELISA) IgG serologic test for 
H pylori diagnosis (HEL-P test, Park Co, Athens, Greece) 
was used for the detection of H. pylori positive patients in 
accordance with the manufacturer’s guidelines. A positive, 
result was assigned when the concentration of IgG antibod-
ies against H pylori was greater than 25 U/mL. The positive 
serums were further examined by western-blot IgG assay for 
the cytotoxin-associated gene A (CagA) protein. Gastrin in 
serum was assayed by a competitive radioimmunoassay us-
ing a rabbit antiserum raised against a gastrin 17 albumin 
conjugate  (Gastrin  RIA,  DIAsource  ImmunoAssays  S.A, 
Belgium). The antiserum used in this assay cross reacts with 
gastrin-34 and the sulphated forms of gastrin-17 and gas-
trin-34. Normal were considered when values < 100 pg/mL.
In all cancer patients colorectal malignancy was iden-
tified by colonoscopy and histopathological examination of 
the biopsy specimens which were obtained during endos-
copy. 
Exclusion criteria were set in order to achieve the min-
imal effect of external factors regarding the fluctuation of 
the parameters measured. Patients who were receiving gas-
tric  antisecretory  medication  (proton  pump  inhibitors,  H2 
blockers)  and  non-steroidal  anti-inflammatory  drugs  were 
excluded from the study. Moreover, exclusion criteria met 
the positive history of gastroduodenal surgical operations, 
Zollinger-Ellison syndrome and alcohol addiction, so as to 
minimize the impact of the factors above as false positive 
causes of hypergastrinemia.
 
Results
The colorectal cancer patient group comprised from 93 pa-
tients with mean age of 69.1 ± 10.1 years, while the mean 
age of the control group was 64.2 ± 14.8 years, the difference 
being non-significant.
Positivity of anti- H. pylori IgG antibodies was reported 
in 66/93 (71%) in the colorectal cancer group, while in the 
control  group  presence  of  the  antibodies  was  detected in 
13/20 patients (65%), the difference having non-statistical 
significance (P = n.s.).
The prevalence of cagA protein expression in the anti- 
H. pylori IgG+ patients were  higher in the colorectal cancer 
group (56% positivity), when compared to the control group 
(38,4% positivity). However, the difference was not of statis-
tical significance (P = n.s).
The  mean  levels  of  serum  gastrin  levels  in  the  two 
groups did not significantly differ (Ca group 51.1 ± 36.6 pg/
mL vs Control 49.8 ± 17.6, P = n.s.). Furthermore, the mean 
gastrin levels were not significantly higher in patients with 
colorectal cancer and H. pylori infection (mean value: 51 
pg/mL), compared with the negative for infection colorectal 
Figure 1. Serum gastrin levels in relation to colon cancer stage. There are no statistical differences between groups.
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cancer patients (mean value: 51.6 pg/mL) and the control 
group (P = n.s.).
The analysis showed that there was no statistically sig-
nificant difference of the serum gastrin levels in the patients 
with colorectal malignancy in terms of the location of the pri-
mary lesion. Similarly, no statistical significance was found 
when the TNM stage of colorectal cancer was correlated to 
serum gastrin levels (Fig. 1). On the contrary, patients with 
infiltrated lymph nodes had higher gastrin levels than the pa-
tients without metastases, with the results reaching statistical 
significance (53.6 pg/mL vs 41.06 pg/mL, P = 0.025).
Discussion
  
The role of H. pylori infection and hypergastrinemia in the 
development of colorectal carcinogenesis has been a matter 
of scientific debate, with controversial findings up to pres-
ent. Gastrin is a 17-aminoacid polypeptide, produced by the 
G-cells of the gastric antrum, duodenum and pancreas. The 
hormone is involved in the secretion of gastric acid from the 
parietal cells of the stomach, as well as in the regulation of 
pancreatic enzyme activity and also appears to play an im-
portant role in the modulation of gastric emptying [6]. As it 
comes to colorectal cancer, hypergastrinemia has been re-
ported to be associated with increased risk for colorectal ma-
lignancy, as the hormone is considered to serve as a growth 
factor  of  normal  colonic  epithelium  [7-9].  In  addition, 
it appears that patients with elevated gastrin levels due to 
Zollinger-Ellison syndrome have higher markers of colonic 
proliferation [10]. On the other hand, in a study by Orbuch et 
al (1996), performed similarly in patients with Zollinger-El-
lison syndrome, the results showed no significant correlation 
between hypergastrinemia and increased risk of colorectal 
cancer [11]. Moreover, Bombski et al (2003) have demon-
strated a decline in preoperatively elevated serum gastrin 
levels after curative surgical operations in colorectal cancer 
patients [12]. 
The  exact  mechanism  through  which  gastrin  acts  in 
the  progress  of  colorectal  carcinogenesis  remains  a  mat-
ter of dispute. Many authors have suggested that gastrin is 
produced and secreted by the malignant intestinal cells and 
demonstrate its growth stimulation effects via autocrine or 
paracrine pathways [13, 14]. Focusing in a more molecular 
basis, recent studies have proven that gastrin is related to 
upregulation of expression of inflammatory mediators, such 
as COX-2 and IL-8, whose inhibition can contribute in the 
prevention of colorectal cancer development [15]. In addi-
tion, there seems to be a genetic bridge between hypergas-
trinemia and colorectal cancer, as gastrin expression is in-
duced by the k-ras oncogene [16]. Lastly, there is a mounting 
scientific debate concerning the role of gastrin precursors, 
such as gastrin-gly, which seem to upregulate proangiogenic 
factors, like VEGF in colon cancer cells [17]. Based upon 
these recent data, it is not surprising that gastrin precursors 
and not gastrin itself may be involved in colorectal cancer, 
bridging the gap regarding the presence of hypergastrinemia 
in colorectal cancer patients. Nevertheless, the exact signifi-
cance of gastrin or its precursors in colorectal cancer is still 
a field of scientific investigation and safe conclusions cannot 
be reached yet.
Our results did not demonstrate a statistically significant 
difference of serum gastrin levels in the colorectal cancer 
group  compared  to  controls.  However,  we  did  show  that 
there was a statistically significant increase of serum gastrin 
in patients with lymph node metastases. The measurement 
of gastrin as a predictor of colorectal metastatic lesions in 
the liver has been proposed by Kameyama et al (1993) [18]. 
Moreover, the same research group has reported positive ef-
fect of administration of gastrin antagonists after liver resec-
tion due to colorectal metastatic disease [19].
Another matter of conflict remains the possible correla-
tion of gastrin levels and colorectal cancer stage. Our study 
results were not supportive of a positive correlation between 
gastrin serum levels and the TNM stage of the tumor, as 
proposed in some published studies [20-22]. Similar con-
clusions with our results have reached the study groups of 
Fontanesi et al. and Vanderstraeten et al [23, 24]. However, 
the clinical significance of these findings cannot at present be 
safely interpreted, since the underlying pathophysiological 
pathways remain terra incognita.
Helicobacter pylori infection is one of the most common 
causes  of  hypergastrinemia  and  chronic  atrophic  gastritis 
and also is firmly associated with gastroduodenal ulceration, 
gastric carcinoma and lymphoma, with about 50% of the 
worldwide population being carriers of the pathogen [23]. In 
addition, H. pylori strains that express the cytoxin-associated 
gene (CagA+) are considered to further induce the inflam-
matory  stress  in  the  colonized  gastric  mucosa,  compared 
to the CagA- H. pylori strains, leading more frequently to 
the development of chronic atrophic gastritis, condition di-
rectly related to elevation of gastrin levels, through reverse 
feedback regulation [24-26]. Moreover, if chronic atrophic 
gastritis is established, the following hypochlorhydria may 
result in intestinal overgrowth of acid-sensitive microflora, 
which has also been implicated in colorectal cancer progres-
sion [27], fact that also proposes a potential link between 
colorectal  cancer  and  elevated  gastrin  levels.  The  main 
pathogenic mechanisms which are considered to be involved 
include the occurring hypergastrinemia in cases of atrophic 
gastritis, as described above, the increase of the intraluminal 
ammonia products, which can trigger intracellular tumori-
genic mechanisms, and finally the promotion of systemic 
inflammation, through overexpression of proinflammatory 
cytokines (IL-1, IL-8, TNF-α, etc) and growth factors  (EGF, 
TGF-α, etc) [28]. It is accepted that H. pylori strains that 
express the cytoxin-associated gene (CagA+) are associated 
to even greater increase of local and systemic inflammation 
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[29],  rising  speculations  regarding  a  possible  correlation 
of increased seroprevalence of CagA+ strains in colorectal 
cancer patients, compared to CagA- strains. In our study, 
the prevalence of H. pylori antibodies did not statistically 
differ between the two groups, in accordance to numerous 
previous case-control studies [30-33]. However, there are 
sufficient published data, supportive of increased H. pylori 
seroprevalence  in  colorectal  cancer  patients,  highlighting 
the impact of the pathophysiological mechanisms described 
above as favorable for the development of colorectal neopla-
sia [34-36]. Although recent meta-analyses indicate that H. 
pylori infection slightly increases the risk for the develop-
ment of colorectal cancer (OR increased from 1.36 to 1.58) 
[2, 28], more studies need to be performed in order to either 
confirm or reject the association between H. pylori infection 
and colorectal cancer.
Our results did not show a statistically significant in-
creased  in  the  seroprevalence  of  CagA+  strains  in  the 
colorectal cancer group. This finding is contradictory with 
the results of the research groups of Shmuely et al (2001) 
and Hartwich et al, who reported that CagA+ seropositiv-
ity is associated with increased risk for both gastric and co-
lonic cancer [35, 37]. It would be challenging to speculate 
that the enhanced inflammation status, both systemic and 
gastric, caused by the CagA+ strains could trigger the sys-
tematic cytokines cascade, predisposing to the formation of 
premalignant lesions. Focusing in the focal gastric inflam-
mation, the CagA+ strains, compared to CagA-, are associ-
ated with increased hazard of chronic atrophic gastritis and 
consequently hypergastrinemia, which appears to be related 
to colorectal carcinogenesis, directly or indirectly. At last, it 
can be concluded that CagA+ strains may exert the metabo-
lism of ammonia products in the large intestine, which can 
act as endogenous carcinogens, although further studies are 
required to confirm our hypotheses.
The significance of gastrin and H. pylori infection in 
colorectal cancer progress still appears like a never-ending 
conquest. Our study did not reveal statistically significant 
differences in gastrin levels among colorectal cancer patients 
and controls. Additionally, no correlation occurred between 
gastrin levels and the site of colorectal cancer or the stage 
of the disease. Nevertheless, it appeared that in colorectal 
cancer patients with infiltrated lymph nodes, the levels of 
gastrin were statistically significantly higher compared to 
the patients with no lymph node infiltrations. It would be 
interesting to investigate in future studies the potential role 
of  gastrin  in  the  mechanisms  of  metastasis  of  the  tumor 
cells. Regarding the seroprevalence of H. pylori infection 
in  colorectal  cancer  patients,  no  statistically  significance 
occurred between the two groups of our study. Moreover, 
therewere no statistical significant difference in the preva-
lence of the CagA serotype in the colorectal cancer group, 
when compared to the control group. The specific role of he-
licobacter pylori CagA+ strains should be examined further 
in the effort to elucidate the impact of h. pylori infection in 
the colorectal cancer progress and also to examine the po-
tential of being a target towards the inhibition of colorectal 
cancerogenesis.
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